U.S. Equity Markets Show Modest Decline
U.S. equity markets are pointing modestly lower this Thursday morning, with attention on the earnings season kickoff and any fresh commentary from the Federal Reserve. However, today’s headlines are largely focused on transformative deals and production milestones that are boosting small- and mid-cap stocks.
Key Movers & Catalysts Driving the Tape
Interactive Strength (NASDAQ: TRNR) is the top pre-market performer, surging over 40% after announcing a definitive agreement to acquire Ergatta, a pioneer in game-based connected fitness. This acquisition is expected to increase TRNR’s 2026 pro forma revenue guidance by 50%, exceeding $30 million, with Ergatta projected to contribute over $10 million in revenue and approximately 30% EBITDA margins, primarily from recurring subscriptions that exceed 70%.
The performance-linked structure caps the maximum enterprise value at $19.5 million, with 50% contingent on 2026 EBITDA of around $4 million, providing an attractive multiple of less than 5.0x EBITDA before synergies. TRNR anticipates that the transaction will be immediately accretive, as Ergatta’s cash flow is expected to surpass the initial cash outlay in 2026.
The acquisition will integrate Ergatta’s engaging gaming content, already licensed by iFIT, into TRNR’s existing brands, including Wattbike, FORME, and CLMBR. Ergatta’s customer acquisition expertise is anticipated to enhance U.S. growth across the portfolio, with the closing targeted for Q1 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB) is also active early, experiencing a sharp uptick following the confirmation of its first wave activation for the 2026 production program. Bio-materials have been moved to incubation, initiating the March production run as part of the company’s multi-ton scale-up initiative for recombinant spider silk. CEO Kim Thompson highlighted the disciplined execution towards achieving sustained monthly commercial volumes, solidifying KBLB’s role as the global leader in scalable spider silk manufacturing. This milestone coincides with recent announcements of significant orders and vertical integration concerning mulberry feedstock access, positioning the company for enhanced commercialization opportunities in defense, performance apparel, technical textiles, and medical applications.
Theriva Biologics (NYSE: TOVX) is also trading higher after successfully out-licensing its oral recombinant bovine intestinal alkaline phosphatase asset, SYN-020, to Rasayana Therapeutics for various GI, metabolic, and inflammatory indications. Theriva has received a $300,000 upfront payment and stands to gain up to $38 million in development, regulatory, and sales milestones, along with tiered single-digit royalties. Rasayana will be responsible for all future development and commercialization costs, allowing Theriva to concentrate its resources on its lead pancreatic cancer program, VCN-01. SYN-020, which has shown good tolerability in Phase 1 trials, is set to enter Phase 2, targeting issues such as leaky gut, microbiome health, fat absorption, and inflammation—key concerns in aging and chronic disease.
Further building momentum in the biotech sector, NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has filed 10 new U.S. patent applications to expand its EL-22 and EL-32 technologies into animal health and agriculture. These filings aim to enhance muscle growth and yield in livestock, aquaculture, and poultry, while also targeting emissions reduction and improving animal health. The non-feed additive approaches could lead to better muscle weight returns, lower environmental impact, quicker time to market in aquaculture, and increased poultry yields, placing the company at the crossroads of sustainable agriculture and biopharma innovation.
For more detailed insights, visit Inside Ticker.